Photo of Ole Isacson,  MD

Ole Isacson, MD

Massachusetts General Hospital

Massachusetts General Hospital

Ole Isacson, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Professor, Neurology, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Publications

Powered by Harvard Catalyst
  • Cooper O, Parmar M, Isacson O. Characterization and criteria of embryonic stem and induced pluripotent stem cells for a dopamine replacement therapy. Prog. Brain Res. 2012; 200:265-76. PubMed
  • Lin Z, Zhao Y, Chung CY, Zhou Y, Xiong N, Glatt CE, Isacson O. High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life. FASEB J 2010; 24:2191-200. PubMed
  • Pruszak J, Ludwig W, Blak A, Alavian K, Isacson O. CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells. Stem Cells 2010; 27:2928-40. PubMed
  • Hallett PJ, Cooper O, Isacson O. No evidence for disease-like processes in fetal transplants. Proc Natl Acad Sci U S A 2009; 106:E104; author reply E105. PubMed
  • Chung CY,Koprich JB,Siddiqi H,Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 2009; 29:3365-73. PubMed
  • Soldner F,Hockemeyer D,Beard C,Gao Q,Bell GW,Cook EG,Hargus G,Blak A,Cooper O,Mitalipova M,Isacson O,Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009; 136:964-77. PubMed
  • Zhang J,Xu TX,Hallett PJ,Watanabe M,Grant SG,Isacson O,Yao WD. PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. J Neurosci 2009; 29:2948-60. PubMed
  • Lin L,Lesnick TG,Maraganore DM,Isacson O. Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics. Trends Neurosci 2009; 32:142-9. PubMed
  • Hedlund E,Isacson O. ALS model glia can mediate toxicity to motor neurons derived from human embryonic stem cells. Cell Stem Cell 2008; 3:575-6. PubMed
  • Isacson O,Kordower JH. Future of cell and gene therapies for Parkinson's disease. Ann Neurol 2009; 64 Suppl 2:S122-38. PubMed
  • Seo H,Kim W,Isacson O. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Hum Mol Genet 2008; 17:3144-53. PubMed
  • de Chevigny A,Cooper O,Vinuela A,Reske-Nielsen C,Lagace DC,Eisch AJ,Isacson O. Fate mapping and lineage analyses demonstrate the production of a large number of striatal neuroblasts after transforming growth factor alpha and noggin striatal infusions into the dopamine-depleted striatum. Stem Cells 2008; 26:2349-60. PubMed
  • Sanchez-Pernaute R,Lee H,Patterson M,Reske-Nielsen C,Yoshizaki T,Sonntag KC,Studer L,Isacson O. Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease. Brain 2008; 131:2127-39. PubMed
  • Hedlund EM, Pruszak J, Lardaro T, Ludwig W, Vinuela A, Kim KS, Isacson O. Embryonic Stem (ES) Cell-derived Pitx3-eGFP Midbrain Dopamine Neurons Survive Enrichment by FACS and Function in an Animal Model of Parkinson's Disease. Stem Cells 2008; 26:1526-36. PubMed
  • Viaro R,Sanchez-Pernaute R,Marti M,Trapella C,Isacson O,Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis 2008; 30:430-8. PubMed
  • Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008; 105:5856-61. PubMed
  • Brunlid G, Pruszak J, Holmes B, Isacson O, Sonntag KC. Immature and neurally differentiated mouse embryonic stem cells do not express a functional Fas/Fas ligand system. Stem Cells 2007; 25:2551-8. PubMed
  • Inoue H, Lin L, Lee X, Shao Z, Mendes S, Snodgrass-Belt P, Sweigard H, Engber T, Pepinsky B, Yang L, Beal MF, Mi S, Isacson O. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci U S A 2007; 104:14430-5. PubMed
  • Pruszak J, Sonntag KC, Aung MH, Sanchez-Pernaute R, Isacson O. Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. Stem Cells 2007; 25:2257-68. PubMed
  • Hong S, Hwang DY, Yoon S, Isacson O, Ramezani A, Hawley RG, Kim KS. Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. Mol Ther 2007; 15:1630-9. PubMed
  • Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med 2007; 4:e262. PubMed
  • Seo H, Sonntag KC, Kim W, Cattaneo E, Isacson O. Proteasome Activator Enhances Survival of Huntington's Disease Neuronal Model Cells. PLoS ONE 2007; 2:e238. PubMed
  • Chung S, Shin BS, Hedlund E, Pruszak J, Ferree A, Kang UJ, Isacson O, Kim KS. Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. J Neurochem 2006; 97:1467-80. PubMed
  • Mendez I, Sanchez-Pernaute R, Cooper O, Vi. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005; 128:1498-510. PubMed
  • Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 2005; 14:1709-25. PubMed
Hide